Bronchiectasis Adult Clinical Trial
Official title:
The Role of Airway Microbiota on Clinical Phenotypes and Disease Severity in Bronchiectasis
Bronchiectasis is characterized pathologically by permanent bronchial dilatation and airway inflammation. The pathogenesis of the disease and the inflammatory, infective and molecular drivers of disease progression are not fully understood. The concept of "treatable traits" was proposed as biomarker-directed approach, based on the recognition of clinical phenotype and endotypes, help to personalized treatment options. Airway microbiota, including bacteria, NTM and fungus, have important but different inflammatory process in bronchiectasis. Our study will provide a new concept that airway microbiota might involve in the airway and systemic inflammation, mucus hypersecretion, as well as the airway damage, remodeling, and frequent exacerbations in bronchiectasis, thus leading to the deterioration of disease severity. Bronchiectasis remains a major cause of respiratory morbidity and treatment is generally only partly successful. Our study will give more clues about the mechanisms on the inflammatory pathway and the probably different response among patients with different isolated microbiota from airways.
Bronchiectasis is characterized pathologically by permanent bronchial dilatation and airway inflammation, and clinically by productive cough, hemoptysis and periodic infectious exacerbations. The pathogenesis of the disease and the inflammatory, infective and molecular drivers of disease progression are not fully understood. Current available therapeutic options have shown only a modest impact on disease outcomes in randomized clinical trials. The concept of "treatable traits" was proposed as biomarker-directed approach, based on the recognition of clinical phenotype and endotypes, help to personalized treatment options. Potential treatable traits of airways disease into four broad categories: pulmonary, extra-pulmonary, etiological, and behavior and lifestyle treatable traits. Airway microbiota, including bacteria, NTM and fungus, have important but different inflammatory process in bronchiectasis. Our study will provide a new concept that airway microbiota might involve in the airway and systemic inflammation, mucus hypersecretion, as well as the airway damage, remodeling, and frequent exacerbations in bronchiectasis, thus leading to the deterioration of disease severity. Bronchiectasis remains a major cause of respiratory morbidity and treatment is generally only partly successful. Our study will give more clues about the mechanisms by which the immunomodulatory medications (macrolides) on the inflammatory pathway and the probably different response among patients with different isolated microbiota from airways. Thus, our results will not only shed light on the airway microbiota inflammatory mechanisms responsible for disease severity, but also provide a new therapeutic direction. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04142827 -
The Effect of Long Term Therapy With High Flow Humidification Compared to Usual Care in Patients With Bronchiectasis (BX)
|
N/A | |
Recruiting |
NCT06093191 -
Tobramycin Inhalation Solution for Pseudomonas Aeruginosa Eradication in Bronchiectasis
|
Phase 4 | |
Recruiting |
NCT06393257 -
Airway Clearance Technique of Oscillation and Lung Expansion in Bronchiectasis
|
N/A | |
Not yet recruiting |
NCT04509661 -
Efficacy and Safety of Inhaled Bronchodilator in Non-CF Bronchiectasis With Airflow Limitation
|
Phase 4 | |
Recruiting |
NCT06017739 -
Expiratory Flow Accelerator (Efa) vs Efa + High Flow in Chronic COPD and Bronchiectasis
|
N/A | |
Completed |
NCT04435327 -
Lung Damage Caused by SARS-CoV-2 Pneumonia (COVID-19)
|
||
Recruiting |
NCT03715322 -
Tobramycin in Bronchiectasis Colonized With Pseudmonas Aeruginosa
|
Phase 3 | |
Recruiting |
NCT03696290 -
Value of Inhaled Treatment With Aztreonam Lysine in Bronchiectasis
|
Phase 2 | |
Recruiting |
NCT04658277 -
Effect of Long Term Clarithromycin for Prevention of Exacerbations in Non-cystic Fibrosis Bronchiectasis in Asian Populations
|
N/A | |
Completed |
NCT04744220 -
Evaluation of the Effect of Yoga Training on Functional Capacity and Quality of Life in Patients With Bronchiectasis
|
N/A | |
Completed |
NCT05764343 -
The Effect of Immediate Smoking Cessation Interventions for Smokers With Chronic Airway Diseases
|
N/A | |
Recruiting |
NCT05582798 -
Bronchiectasis Alpha-1 Augmentation Trial- Modulating Airway Neutrophil Function
|
Phase 4 | |
Not yet recruiting |
NCT04987827 -
Investigating the Clinical Features and Prognosis of Bronchiectasis Adult Patients
|
||
Recruiting |
NCT03791086 -
The BRIDGE Study - Bronchiectasis Research Involving Databases, Genomics and Endotyping
|
||
Completed |
NCT04234789 -
Predictors of Physical Activity Performance and Dynamic Hyperinflation in Patients With Bronchiectasis
|
N/A | |
Recruiting |
NCT04865861 -
The Characteristic of Airway Microbiome Profiling of COPD-bronchiectasis Overlap Patients and Its Association With Acute Exacerbation
|
||
Completed |
NCT04742270 -
Home Airway Clearance in Patients With Bronchiectasis (Home-Care Bronchiectasis)
|
N/A | |
Recruiting |
NCT05330637 -
Study on the Influence of Climatic and Environmental Factors on Respiratory Diseases in Sanya, Hainan Province, China.
|
||
Completed |
NCT05989360 -
The Utility of Lung Clearance Index in Ethnic Groups and in Disease
|
N/A | |
Completed |
NCT03125174 -
Characterization of Airway Mucus in Bronchiectasis Patients and Healthy Controls
|
N/A |